Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Impact · against what's priced in

Intellia (NTLA) reports strong Phase 3 efficacy and safety data for lonvo-z, which provides the first definitive clinical validation for its in vivo CRISPR platform. The transition to a rolling BLA submission and a targeted 2027 launch creates a concrete path to commercialization for the HAE candidate.

NTLA+0.70: No priced-in read yet

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

What matters in this story

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

What matters in this story

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

How each ticker is affected

Track these names every morning.

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

What matters in this story

Next reads from the same story arc

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

What matters in this story

Next reads from the same story arc

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

How each ticker is affected

Track these names every morning.

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026